Work

Supplementary Figure 12 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure 12. The receiver operating characteristic curves of TAA burden and CTA burden for predicting ICB benefits in two HNSC ICB clinical trial datasets. Left panel shows a neoadjuvant trial of advanced-stage HNSC patients treated with the anti-PD-1 antibody nivolumab (Obradovic dataset). Right panel shows patients recruited for a neoadjuvant pembrolizumab trial (Uppaluri dataset). All patient subjects in the two trials are included in the analyses.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W7165054966
Cites:
Cited by:
Related to: 10